Alimera Sciences Company Profile (NASDAQ:ALIM)

About Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences logoAlimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALIM
  • CUSIP: N/A
  • Web: www.alimerasciences.com
Capitalization:
  • Market Cap: $97.29 million
  • Outstanding Shares: 64,862,000
Average Prices:
  • 50 Day Moving Avg: $1.46
  • 200 Day Moving Avg: $1.28
  • 52 Week Range: $1.01 - $2.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 150.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $35.15 million
  • Price / Sales: 2.77
  • Book Value: ($0.75) per share
  • Price / Book: -2.00
Profitability:
  • EBIDTA: ($21,800,000.00)
  • Net Margins: -128.77%
  • Return on Assets: -55.69%
Debt:
  • Debt-to-Equity Ratio: -0.87%
  • Current Ratio: 6.57%
  • Quick Ratio: 6.46%
Misc:
  • Average Volume: 642,567 shs.
  • Beta: 3.13
  • Short Ratio: 1.57
 

Frequently Asked Questions for Alimera Sciences (NASDAQ:ALIM)

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

How were Alimera Sciences' earnings last quarter?

Alimera Sciences Inc (NASDAQ:ALIM) posted its earnings results on Monday, May, 8th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The company had revenue of $6.62 million for the quarter, compared to analysts' expectations of $8.80 million. The business's quarterly revenue was up 14.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.22) earnings per share. View Alimera Sciences' Earnings History.

Where is Alimera Sciences' stock going? Where will Alimera Sciences' stock price be in 2017?

2 equities research analysts have issued 1 year price targets for Alimera Sciences' stock. Their forecasts range from $3.00 to $4.00. On average, they expect Alimera Sciences' stock price to reach $3.50 in the next twelve months. View Analyst Ratings for Alimera Sciences.

What are analysts saying about Alimera Sciences stock?

Here are some recent quotes from research analysts about Alimera Sciences stock:

  • 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (4/5/2017)
  • 2. Cowen and Company analysts commented, "ALIM pre-announced 2Q16 revenue of $9.3-9.5M ahead of our estimate of $7.8M." (7/26/2016)

Who are some of Alimera Sciences' key competitors?

Who owns Alimera Sciences stock?

Alimera Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LLC (4.65%), Stonepine Capital Management LLC (0.00%), Vanguard Group Inc. (0.00%), Goldman Sachs Group Inc. (0.78%), Kennedy Capital Management Inc. (0.00%) and Parkwood LLC (0.35%). Company insiders that own Alimera Sciences stock include C Daniel Myers, Calvin W Roberts, James E Flynn, Kenneth Green, LP Bavp, Richard S Eiswirth Jr and Richard S Eiswirth, Jr. View Institutional Ownership Trends for Alimera Sciences.

Who sold Alimera Sciences stock? Who is selling Alimera Sciences stock?

Alimera Sciences' stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and Goldman Sachs Group Inc.. Company insiders that have sold Alimera Sciences stock in the last year include C Daniel Myers and Richard S Eiswirth Jr. View Insider Buying and Selling for Alimera Sciences.

Who bought Alimera Sciences stock? Who is buying Alimera Sciences stock?

Alimera Sciences' stock was acquired by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., Vanguard Group Inc., KCG Holdings Inc. and Geode Capital Management LLC. Company insiders that have bought Alimera Sciences stock in the last two years include Calvin W Roberts and James E Flynn. View Insider Buying and Selling for Alimera Sciences.

How do I buy Alimera Sciences stock?

Shares of Alimera Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alimera Sciences stock cost?

One share of Alimera Sciences stock can currently be purchased for approximately $1.50.

Analyst Ratings

Consensus Ratings for Alimera Sciences (NASDAQ:ALIM) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (133.33% upside)

Analysts' Ratings History for Alimera Sciences (NASDAQ:ALIM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2017Rodman & RenshawInitiated CoverageBuy -> Buy$4.00HighView Rating Details
3/2/2017Cowen and CompanySet Price TargetBuy$3.00N/AView Rating Details
3/4/2016Cantor FitzgeraldLower Price TargetBuy$6.00 -> $5.00N/AView Rating Details
11/26/2015Credit Suisse Group AGLower Price Target$5.00 -> $4.00N/AView Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for Alimera Sciences (NASDAQ:ALIM)
Earnings by Quarter for Alimera Sciences (NASDAQ:ALIM)
Earnings History by Quarter for Alimera Sciences (NASDAQ:ALIM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.08)($0.10)$8.80 million$6.62 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.07)($0.10)$10.60 million$10.70 millionViewListenView Earnings Details
11/2/2016Q316($0.11)($0.16)$10.53 million$8.30 millionViewN/AView Earnings Details
8/3/2016Q2($0.19)($0.17)$8.42 million$3.80 millionViewN/AView Earnings Details
5/4/2016Q1($0.19)($0.22)$5.83 million$5.80 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.21)$6.96 million$6.90 millionViewN/AView Earnings Details
8/10/2015Q215($0.22)($0.25)$6.49 million$5.80 millionViewListenView Earnings Details
5/7/2015Q115($0.24)($0.27)$3.90 million$3.90 millionViewN/AView Earnings Details
3/4/2015Q414($0.16)($0.28)$5.11 million$1.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.70)($0.22)$3.75 million$2.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.23)($0.15)$2.70 million$2.19 millionViewN/AView Earnings Details
5/8/2014Q114($0.25)($0.20)$1.15 million$2.08 millionViewN/AView Earnings Details
2/27/2014Q413($0.29)($0.24)$0.75 million$0.94 millionViewN/AView Earnings Details
11/11/2013Q313($0.30)($0.26)$0.38 million$0.76 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.24)($0.30)$3.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.26)($0.27)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.23)($0.17)ViewN/AView Earnings Details
11/7/2012Q312($0.19)($0.17)ViewN/AView Earnings Details
3/8/2012($0.24)($0.19)ViewN/AView Earnings Details
11/3/2011($0.19)($0.21)ViewN/AView Earnings Details
8/4/2011($0.18)($0.17)ViewN/AView Earnings Details
5/5/2011($0.20)($0.15)ViewN/AView Earnings Details
2/10/2011($0.22)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alimera Sciences (NASDAQ:ALIM)
Current Year EPS Consensus Estimate: $-0.17 EPS
Next Year EPS Consensus Estimate: $0.01 EPS

Dividends

Dividend History for Alimera Sciences (NASDAQ:ALIM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alimera Sciences (NASDAQ:ALIM)
Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 53.26%
Insider Trades by Quarter for Alimera Sciences (NASDAQ:ALIM)
Institutional Ownership by Quarter for Alimera Sciences (NASDAQ:ALIM)
Insider Trades by Quarter for Alimera Sciences (NASDAQ:ALIM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/10/2017C. Daniel MyersCEOSell21,172$1.39$29,429.08View SEC Filing  
9/15/2016Richard S Eiswirth JrInsiderSell51,471$1.51$77,721.21View SEC Filing  
4/21/2016L.P. BavpMajor ShareholderSell478,673$2.59$1,239,763.07View SEC Filing  
12/16/2015Richard S. Eiswirth, Jr.CFOSell46,669$2.31$107,805.39View SEC Filing  
12/8/2015James E FlynnInsiderBuy272,249$3.01$819,469.49View SEC Filing  
12/3/2015James E FlynnInsiderBuy243,252$3.00$729,756.00View SEC Filing  
10/30/2015James E FlynnInsiderBuy16,542$3.00$49,626.00View SEC Filing  
10/28/2015James E FlynnInsiderBuy59,342$3.00$178,026.00View SEC Filing  
10/26/2015James E FlynnInsiderBuy60,364$3.00$181,092.00View SEC Filing  
10/21/2015James E FlynnMajor ShareholderBuy160,684$3.00$482,052.00View SEC Filing  
10/20/2015James E FlynnMajor ShareholderBuy100,130$3.00$300,390.00View SEC Filing  
10/19/2015James E FlynnMajor ShareholderBuy129,226$2.92$377,339.92View SEC Filing  
10/15/2015Richard S. Eiswirth, Jr.CFOSell13,625$2.69$36,651.25View SEC Filing  
10/9/2015James E FlynnInsiderBuy321,785$2.42$778,719.70View SEC Filing  
9/3/2015Calvin W RobertsDirectorBuy6,424$3.00$19,272.00View SEC Filing  
8/21/2015Kenneth GreenSVPSell20,000$3.29$65,800.00View SEC Filing  
8/17/2015Kenneth GreenSVPSell20,000$3.90$78,000.00View SEC Filing  
6/26/2015L.P. BavpMajor ShareholderSell1,024$5.00$5,120.00View SEC Filing  
6/19/2015L.P. BavpMajor ShareholderSell5,568$5.00$27,840.00View SEC Filing  
5/1/2015C. Daniel MyersCEOSell2,000$4.37$8,740.00View SEC Filing  
4/27/2015L.P. BavpMajor ShareholderSell3,114$5.02$15,632.28View SEC Filing  
4/23/2015L.P. BavpMajor ShareholderSell4,362$5.00$21,810.00View SEC Filing  
4/20/2015L.P. BavpMajor ShareholderSell30,300$5.03$152,409.00View SEC Filing  
4/15/2015L.P. BavpMajor ShareholderSell35,800$5.03$180,074.00View SEC Filing  
4/14/2015L.P. BavpMajor ShareholderSell18,400$5.01$92,184.00View SEC Filing  
4/13/2015L.P. BavpMajor ShareholderSell100$5.00$500.00View SEC Filing  
3/6/2015Richard S Eiswirth JrCFOBuy10,000$4.84$48,400.00View SEC Filing  
3/2/2015C. Daniel MyersCEOSell2,000$5.21$10,420.00View SEC Filing  
1/2/2015C. Daniel MyersCEOSell2,000$5.51$11,020.00View SEC Filing  
1/2/2015David HollandSVPSell5,000$5.56$27,800.00View SEC Filing  
12/1/2014C. Daniel MyersCEOSell2,000$5.99$11,980.00View SEC Filing  
12/1/2014David HollandSVPSell5,000$5.71$28,550.00View SEC Filing  
10/27/2014L.P. BavpMajor ShareholderSell57,918$6.34$367,200.12View SEC Filing  
10/1/2014C. Daniel MyersCEOSell2,000$5.42$10,840.00View SEC Filing  
10/1/2014David HollandSVPSell5,000$5.26$26,300.00View SEC Filing  
10/1/2014Patrick LeeMajor ShareholderSell621,191$5.42$3,366,855.22View SEC Filing  
9/30/2014Patrick LeeMajor ShareholderSell354,062$5.42$1,919,016.04View SEC Filing  
9/29/2014Patrick LeeMajor ShareholderSell240,662$5.47$1,316,421.14View SEC Filing  
9/11/2014L.P. BavpMajor ShareholderSell2,816$6.25$17,600.00View SEC Filing  
9/4/2014L.P. BavpMajor ShareholderSell39,500$6.33$250,035.00View SEC Filing  
8/29/2014L.P. BavpMajor ShareholderSell7,400$6.27$46,398.00View SEC Filing  
8/28/2014L.P. BavpMajor ShareholderSell3,000$6.27$18,810.00View SEC Filing  
8/1/2014David HollandSVPSell5,000$5.64$28,200.00View SEC Filing  
7/1/2014David HollandSVPSell5,000$6.02$30,100.00View SEC Filing  
5/1/2014David HollandSVPSell5,000$5.93$29,650.00View SEC Filing  
3/4/2014C. Daniel MyersCEOSell22,775$7.10$161,702.50View SEC Filing  
3/4/2014David HollandSVPSell10,000$6.84$68,400.00View SEC Filing  
3/4/2014Susan CaballaInsiderSell8,931$7.01$62,606.31View SEC Filing  
1/16/2014Domain Partners Vi, L.P.Major ShareholderSell296,760$6.39$1,896,296.40View SEC Filing  
7/17/2013Polaris Venture Management CoInsiderSell122,937$4.80$590,097.60View SEC Filing  
6/20/2013Domain Partners Vi, L.P.Major ShareholderSell10,516$5.01$52,685.16View SEC Filing  
6/19/2013Domain Partners Vi, L.P.Major ShareholderSell55,278$5.39$297,948.42View SEC Filing  
6/18/2013Polaris Venture Management CoInsiderSell37,063$5.44$201,622.72View SEC Filing  
6/17/2013Domain Partners Vi, L.P.Major ShareholderSell126,709$5.29$670,290.61View SEC Filing  
6/11/2013Domain Partners Vi, L.P.Major ShareholderSell5,337$5.00$26,685.00View SEC Filing  
5/17/2013David HollandSVPSell30,000$4.13$123,900.00View SEC Filing  
5/16/2013Domain Partners Vi, L.P.Major ShareholderSell44,242$4.60$203,513.20View SEC Filing  
12/13/2012Peter J Pizzo IIIDirectorBuy5,000$1.44$7,200.00View SEC Filing  
12/3/2012C. Daniel MyersCEOSell7,700$1.95$15,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alimera Sciences (NASDAQ:ALIM)
Latest Headlines for Alimera Sciences (NASDAQ:ALIM)
Source:
DateHeadline
seekingalpha.com logoAlimera Sciences' (ALIM) CEO Dan Myers on Q1 2017 Results ... - Seeking Alpha
seekingalpha.com - May 10 at 9:26 AM
globenewswire.com logoAlimera Sciences Reports First Quarter 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:26 AM
finance.yahoo.com logoEdited Transcript of ALIM earnings conference call or presentation 9-May-17 12:00pm GMT
finance.yahoo.com - May 9 at 8:28 PM
americanbankingnews.com logoAlimera Sciences Inc (ALIM) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 9 at 10:22 AM
finance.yahoo.com logoInvestor Network: ALIMERA SCIENCES INC to Host Earnings Call
finance.yahoo.com - May 9 at 9:21 AM
finance.yahoo.com logoAlimera Sciences Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 8:26 PM
marketbeat.com logoAlimera Sciences reports 1Q loss
marketbeat.com - May 8 at 6:22 PM
americanbankingnews.com logoAlimera Sciences (ALIM) Receives Daily Media Impact Score of 0.24
www.americanbankingnews.com - May 4 at 3:54 PM
finance.yahoo.com logoAlimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017
finance.yahoo.com - May 3 at 3:28 PM
finance.yahoo.com logoETFs with exposure to Alimera Sciences, Inc. : May 1, 2017
finance.yahoo.com - May 2 at 7:18 AM
streetinsider.com logoAlimera Sciences (ALIM) Says Data From 27 ILUVIEN Studies to Be Presented at ARVO
www.streetinsider.com - May 1 at 3:31 PM
247wallst.com logo7 Speculative Analyst Stocks Called to Rise 100% or More
247wallst.com - May 1 at 3:31 PM
americanbankingnews.com logoSomewhat Negative Media Coverage Likely to Impact Alimera Sciences (ALIM) Stock Price
www.americanbankingnews.com - May 1 at 11:44 AM
streetinsider.com logoAlimera Sciences (ALIM) Says Data From 27 ILUVIEN Studies to Be Presented at ARVO - StreetInsider.com
www.streetinsider.com - May 1 at 9:45 AM
finance.yahoo.com logoAlimera Sciences Announces Data From 27 ILUVIEN® Studies to Be Presented at 2017 ARVO
finance.yahoo.com - May 1 at 9:45 AM
benzinga.com logoAlimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored - Benzinga
www.benzinga.com - April 30 at 4:46 PM
americanbankingnews.com logoAlimera Sciences Inc (ALIM) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 30 at 7:06 AM
americanbankingnews.com logoAlimera Sciences (ALIM) Receiving Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 28 at 11:02 AM
americanbankingnews.com logoAlimera Sciences Inc (ALIM) Now Covered by Rodman & Renshaw
www.americanbankingnews.com - April 27 at 10:12 PM
americanbankingnews.com logoAlimera Sciences (ALIM) Getting Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 24 at 12:18 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Likely to Affect Alimera Sciences (ALIM) Share Price
www.americanbankingnews.com - April 21 at 10:07 AM
finance.yahoo.com logoETFs with exposure to Alimera Sciences, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 3:30 PM
americanbankingnews.com logo Brokerages Anticipate Alimera Sciences Inc (ALIM) Will Announce Earnings of -$0.07 Per Share
www.americanbankingnews.com - April 18 at 2:56 PM
americanbankingnews.com logoShort Interest in Alimera Sciences Inc (ALIM) Rises By 23.9%
www.americanbankingnews.com - April 8 at 10:22 PM
finance.yahoo.com logoETFs with exposure to Alimera Sciences, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 8:28 PM
americanbankingnews.com logoAlimera Sciences Inc (ALIM) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 5 at 4:52 PM
americanbankingnews.com logoAlimera Sciences Inc (ALIM) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 10:22 AM
americanbankingnews.com logoAlimera Sciences Inc (ALIM) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 5:04 PM
americanbankingnews.com logoAlimera Sciences Inc (ALIM) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 8:52 AM
americanbankingnews.com logoZacks: Analysts Set $3.00 Price Target for Alimera Sciences Inc (ALIM)
www.americanbankingnews.com - March 20 at 12:22 PM
americanbankingnews.com logoAlimera Sciences Inc (ALIM) CEO Sells $29,429.08 in Stock
www.americanbankingnews.com - March 13 at 10:49 PM
streetinsider.com logoAlimera Sciences (ALIM) Signs Exclusive Agreement with Brill Pharma to Distribute ILUVIEN® in Spain
www.streetinsider.com - March 13 at 8:33 PM
streetinsider.com logoAlimera Sciences (ALIM) Signs Exclusive Agreement with Brill ... - StreetInsider.com
www.streetinsider.com - March 13 at 3:33 PM
finance.yahoo.com logoAlimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain
finance.yahoo.com - March 13 at 3:33 PM
finance.yahoo.com logoALIMERA SCIENCES INC Financials
finance.yahoo.com - March 9 at 3:31 PM
finance.yahoo.com logoAlimera Sciences to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 7 at 3:27 PM
biz.yahoo.com logoALIMERA SCIENCES INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 3 at 8:44 PM
finance.yahoo.com logoAlimera Sciences to Present at the 37th Annual Cowen Health Care Conference
finance.yahoo.com - March 3 at 3:42 PM
finance.yahoo.com logoEdited Transcript of ALIM earnings conference call or presentation 2-Mar-17 3:00pm GMT
finance.yahoo.com - March 3 at 1:45 AM
reuters.com logoBRIEF-Alimera Sciences Q4 adjusted non-gaap loss per share $0.10 - Reuters
www.reuters.com - March 2 at 3:43 PM
rttnews.com logoEARNINGS SUMMARY: Details of Alimera Sciences, Inc. Q4 Earnings Report
www.rttnews.com - March 1 at 8:29 PM
us.rd.yahoo.com logoAlimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 1 at 8:29 PM
biz.yahoo.com logoALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
us.rd.yahoo.com - March 1 at 8:29 PM
biz.yahoo.com logoQ4 2016 Alimera Sciences Inc Earnings Release - After Market Close
biz.yahoo.com - March 1 at 8:13 AM
finance.yahoo.com logoAlimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017
finance.yahoo.com - February 23 at 3:28 PM
reuters.com logoBRIEF-Alimera Sciences and Knight Therapeutics file new drug submission for iluvien in Canada
www.reuters.com - February 23 at 1:36 AM
us.rd.yahoo.com logoAlimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in Canada
us.rd.yahoo.com - February 23 at 1:36 AM
us.rd.yahoo.com logo8:05 am Alimera Sciences and Knight Therapeutics announce that Knight's New Drug Submission for ILUVIEN has been accepted for review by Health Canada
us.rd.yahoo.com - February 23 at 1:36 AM
finance.yahoo.com logoAlimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada - Yahoo Finance
finance.yahoo.com - February 22 at 11:35 AM
seekingalpha.com logoAlimera up 10% on ILUVIEN regulatory filing in Canada - Seeking Alpha
seekingalpha.com - February 22 at 11:35 AM

Social

Alimera Sciences (ALIM) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff